• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

by | Feb 1, 2025 | Myeloma News

Source: Pharmacy Times articles Expert weighs in on data from the AQUILA trial and Johnson & Johnson’s approval request for daratumumab for smoldering multiple myeloma. Read More

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study

by | Jan 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma

by | Jan 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction

by | Jan 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma

by | Jan 29, 2025 | Myeloma News

Source: Pharmacy Times articles Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival. Read More

PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma

by | Jan 27, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT